Lebanon
Tuberculosis profile
Population  2013 4.8 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.042 (0.012–0.092) 0.86 (0.24–1.9)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 0.9 (0.32–1.8) 19 (6.7–37)
Incidence  (includes HIV+TB) 0.76 (0.66–0.86) 16 (14–18)
Incidence (HIV+TB only)        
Case detection, all forms (%) 91 (80–110)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.1 (0.1–3.8) 29 (3.7–71)
MDR-TB cases among notified pulmonary
TB cases
4 (0–15) 2 (0–6)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 248   8
Pulmonary, clinically diagnosed 142   0
Extrapulmonary 291   0
       
Total new and relapse 689    
Previously treated, excluding relapses 0    
Total cases notified 689    
Among 681 new cases:
52 (8%) cases aged under 15 years; male:female ratio: 0.7
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 23 (9%) 7 (88%) 30
Laboratory-confirmed RR-/MDR-TB cases     10
Patients started on MDR-TB treatment     8
TB/HIV 2013 Number (%)
TB patients with known HIV status 354 (51)
HIV-positive TB patients 5 (1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 5 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 5 (100)
HIV-positive people screened for TB 102  
HIV-positive people provided with IPT 50  
Treatment success rate (%)
New and relapse cases registered in 2012 71
Previously treated cases, excluding relapse, registered in 2012  
HIV-positive TB cases, all types, registered in 2012 0
RR-/MDR-TB cases started on second-line treatment in 2011 100
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 3.4
Culture (per 5 million population) 18.9
Drug susceptibility testing (per 5 million population) 0.9
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) <1
% Funded domestically 91%
% Funded internationally 0%
% Unfunded 9%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-31 Data: www.who.int/tb/data